Abstract
Primary central nervous system lymphoma (PCNSL) is a rare lymphoma that involves the central nervous system. The standard treatment involves chemotherapy with high-dose methotrexate. To the best of our knowledge, this is the first reported case of employing checkpoint inhibitor, nivolumab, alone to treat a patient with PCNSL who could not tolerate the induction therapy. In aggressive cases of PCNSL where chemotherapy may become futile, stand-alone checkpoint inhibitors should be considered as the front-line treatment protocol.
Recommended Citation
El-Tawab, Rasha; Hamada, Abdulaziz; Elhagracy, Rehab; Pinto, Karen; and Alshemmari, Salem
(2023)
"Promising effect of PDL1 inhibitors in the front-line management of primary aggressive central nervous system lymphoma: A case report,"
Hematology/Oncology and Stem Cell Therapy: Vol. 16
:
Iss.
2
, Article 8.
Available at: https://doi.org/10.1016/j.hemonc.2020.06.003
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Included in
Cancer Biology Commons, Hematology Commons, Oncology Commons
